Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 3Recurrence 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Blast Crisis 1

Interventions

Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Methotrexate 3Cytarabine 3venetoclax 2ponatinib 2merphos 2fludarabine phosphate 2Tacrolimus 2Idarubicin 2Etoposide 2Cyclosporine 2Cyclophosphamide 2Cladribine 2Busulfan 2midostaurin 1gilteritinib 1blinatumomab 1Thiotepa 1Sirolimus 1Razoxane 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Melphalan 1Injections 1Gemtuzumab 1Dexrazoxane 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × Decitabine × 30 days × Clear all
NCT04188405 2026-06-05

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

Phase 2 Completed
20 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡